Cancer Institute Clinical Trials Lymphoma-Leukemia-Myeloma

Lymphoma

#130409 NCT01855750
Title:
PHOENIX Protocol PCI-32765dbl3001: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Study Location:
Temple Main Campus

Leukemia

#50148 NCT00074282
Title: Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or REfractory Patients with Chronic Lymphocytic Leukemia
Study Location: Temple Main Campus

Myeloma

#130437 NCT01564537
Title:
Tourmaline-MM2 Protocol C16014: A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Study Location:
Temple Main Campus

For more information or to enroll in a study, please call 254-724-5407.


Print
Text Size
A
A
A